A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.
Multicentre, open label, prospective, single arm study
Blood and bone marrow samples are collected for assessment of minimal residual disease (MRd) and for purification and storage for potential future exploratory biomarker studies
TRIAL PRINCIPAL INVESTIGATOR
Professor Andrew Spencer
2016 – 2018
45 patients with relapsed refractory multiple myeloma (RR MM) who have received 1-3 prior lines of therapy
Closed to recruitment